A 72% Premium and $1.27 Billion: Inside the Take-Private Reshaping Medical Device M&A

American Industrial Partners' all-cash acquisition of Avanos Medical at a striking premium signals where private equity sees value in a healthcare sector otherwise practicing capital discipline.

American Industrial Partners has agreed to acquire Avanos Medical in an all-cash take-private deal worth approximately $1.272 billion, a roughly 72% premium to Avanos's pre-announcement share price.

The deal closed following a July 22 shareholder vote, arriving the same month digital health investors deployed $7.4 billion in H1 2026 funding — concentrated in a small number of mega-deals.

Together, the two data points describe a healthcare capital environment rewarding conviction in specific assets rather than broad-based enthusiasm.

A 72% premium is not a number private equity firms attach to targets casually. American Industrial Partners' agreement to take Avanos Medical private for roughly $1.272 billion, at $25.00 per share, says as much about AIP's confidence in extracting value operationally as it does about where Avanos traded before the announcement. AIP describes itself as an operationally oriented investor — a firm that makes money by running acquired businesses differently, not simply by financial engineering — and a premium this size typically signals a buyer who believes the target's public-market valuation was mispricing an operational turnaround opportunity that a public shareholder base wasn't positioned to see or wait for.

The broader healthcare capital backdrop makes the specificity of this deal more interesting. Digital health investors deployed $7.4 billion in the first half of 2026, but nearly half of that concentrated into a small number of mega-deals — not a broad rising tide lifting every health-tech company. Read together, the Avanos take-private and the concentrated digital health funding pattern describe the same underlying discipline: healthcare capital in 2026 is not scarce, but it is unusually selective, rewarding specific, well-understood value-creation theses over sector-wide optimism. For medical device and health-tech executives evaluating their own capital-raising prospects, the operative question isn't "is healthcare capital available" — it's whether their specific story is sharp enough to be one of the deals investors are concentrating around.